Optum Ventures co-led a series B round that took the chronic disease management platform's total funding to $50m.

The pharmaceutical firm has transferred China-based business development director Manabu Aruga to its Tokyo headquarters where he will oversee corporate VC deals in Asia.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.

The targeted oncology drug developer, which counts Bristol Myers Squibb and Celgene as investors, is floating above its range in an upsized offering.

Kaiser Permanente contributed to a round that pushed the total raised by the ceullar cancer therapy developer to $300m.

Rabies and meningities vaccine producer Kanghua Biological, which counts Aokang and Tigermed as investors, has floated in its home country of China.

The healthcare data integrator boosted its overall funding to $53m in a series B round led by Blue Venture Fund that included Echo Health Ventures.

Backed by Intel and HTC as of its launch early last year, Proprio has now raised a total of $30m to commercialise its multi-camera surgical imaging system.

Grand Decade and existing investor Boehringer Ingelheim Venture Fund helped supply $38.2m for the mRNA immunotherapy developer and Vrije Universiteit Brussel spinout.